{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T18:07:28Z","timestamp":1776535648585,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210693"],"award-info":[{"award-number":["BK20210693"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204443"],"award-info":[{"award-number":["82204443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["Z2021064"],"award-info":[{"award-number":["Z2021064"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34030","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:49:08Z","timestamp":1719978548000},"page":"e34030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["GL-V9 induce apoptosis of CML cells via MAPK signaling pathway"],"prefix":"10.1016","volume":"10","author":[{"given":"Fengyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e34030_bib1","article-title":"Targeting BCR-ABL1-positive leukaemias: a review article","volume":"1","author":"Steven","year":"2024","journal-title":"Camb Prism Precis Med"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34030_bib2","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Jorge","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34030_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109538","article-title":"BCR::ABLThe molecular signature of and in a chronic myeloid leukemia model","volume":"27","author":"Baassiri","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-018-0732-4","article-title":"Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases","volume":"37","author":"Huang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34030_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.6000\/1929-2279.2018.07.02.3","article-title":"Pharmacotherapeutic options for Philadelphia chromosome- positive CML","volume":"7","author":"Patel","year":"2018","journal-title":"J. Cancer Res. Updates"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib6","doi-asserted-by":"crossref","DOI":"10.7175\/fe.v18i1.1318","article-title":"Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients","volume":"18","author":"Mennini","year":"2017","journal-title":"Farmeconomia Health economics and therapeutic pathways"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e34030_bib7","article-title":"Molecular response with nilotinib in patients with Philadelphia negative (Ph-) chronic myeloid leukemia in chronic phase (CML-CP): ENEST1st sub-analysis","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34030_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34030_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3383.3383","article-title":"Modelling of TKI resistance in CML cell lines: kinase domain mutations usually arise in the setting of BCR-ABL overexpression","volume":"116","author":"Tang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e34030_bib10","first-page":"131","article-title":"Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia","author":"Martinez-Castillo","year":"2023","journal-title":"Leuk. Res.: A Forum for Studies on Leukemia and Normal Hemopoiesis"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34030_bib11","article-title":"Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML)","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e34030_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127514","article-title":"Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors","volume":"134","author":"Castagnetti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/a-0829-2400","article-title":"Chronische myeloische leukmie","volume":"40","author":"Hochhaus","year":"2019","journal-title":"TumorDiagnostik Ther."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e34030_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-139188","article-title":"Impact of genetic predisposition on glyco-metabolic side effects of TKIs in CML","volume":"136","author":"Iurlo","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34030_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5306\/wjco.v11.i6.308","article-title":"Horn of plenty: value of the international registry for pediatric chronic myeloid leukemia","volume":"11","author":"Suttorp","year":"2020","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34030_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","article-title":"Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy","volume":"8","author":"Liu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e34030_bib17","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34030_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.15212\/AMM-2023-0028","article-title":"Structure-based virtual screening for novel p38 MAPK inhibitors and a biological evaluation","volume":"2","author":"Zheng","year":"2023","journal-title":"Acta Materia Medica"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34030_bib19","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/cas.14878","article-title":"Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer","volume":"112","author":"Schulz","year":"2021","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34030_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050690","article-title":"Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling","volume":"7","author":"Hepburn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e34030_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2019.02.030","article-title":"Triptolide prevents proliferation and migration of Esophageal Squamous Cell Cancer via MAPK\/ERK signaling pathway","volume":"851","author":"Yanchun","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib22","first-page":"115","article-title":"Human estrogen sulfotransferase (EST) enzyme modulates MAPK pathway in human BreastT cancer cell line MCF-7","volume":"12","author":"Cakir","year":"2021","journal-title":"Journal of Applied Bioloical Sciences"},{"issue":"30","key":"10.1016\/j.heliyon.2024.e34030_bib23","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 mapk pathway mediates the growth inhibitory effects of interferon- in bcr-abl-expressing cells","volume":"2001","author":"Mayer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e34030_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/biology12020307","article-title":"Brassinin induces apoptosis, autophagy, and paraptosis via MAPK signaling pathway activation in chronic myelogenous leukemia cells","volume":"12","author":"Min Hee","year":"2023","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34030_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cells9040877","article-title":"Nobiletin promotes megakaryocytic differentiation through the MAPK\/ERK-Dependent EGR1 expression and exerts anti-leukemic effects in human chronic myeloid leukemia (CML) K562 cells","volume":"9","author":"Yen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e34030_bib26","article-title":"Gambogic acid induces death of K562 cells through autophagy and apoptosis mechanisms","volume":"56","author":"Jinhao","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e34030_bib27","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation","volume":"20","author":"Xianping","year":"2013","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.heliyon.2024.e34030_bib28","article-title":"Induction of apoptosis and differentiation by atractylenolide-1 isolated from Atractylodes macrocephala in human leukemia cells","volume":"26","author":"Huey-Lan","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.heliyon.2024.e34030_bib29","article-title":"Chemoproteomics reveals glaucocalyxin A induces mitochondria-dependent apoptosis of leukemia cells via covalently binding to VDAC1","volume":"8","author":"Yehai","year":"2023","journal-title":"Advanced biology"},{"key":"10.1016\/j.heliyon.2024.e34030_bib30","article-title":"Dihydroartemisinin inhibits the Bcr\/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib","volume":"67","author":"Jun","year":"2012","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34030_bib31","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/ptr.7386","article-title":"Wogonin and its analogs for the prevention and treatment of cancer: a systematic review","volume":"36","author":"Banik","year":"2022","journal-title":"Phytother Res. : PT"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34030_bib32","first-page":"33","article-title":"Wogonin inducing apoptosis in breast cancer cell line","volume":"4","author":"Mehdi","year":"2021","journal-title":"Immunoregulation"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34030_bib33","first-page":"185","article-title":"Assessing the antiproliferative potential of a novel combretastatin A4 derivative via modulating apoptosis, MAPK\/ERK and PI3K\/AKT pathways in human breast cancer cells","volume":"28","author":"Nazmy","year":"2023","journal-title":"FBL"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e34030_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.21037\/atm-20-1166","article-title":"Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4\/7 axis in bone marrow microenvironment","volume":"8","author":"Cao","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34030_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41401-019-0270-4","article-title":"LW-213, a newly synthesized flavonoid, induces G2\/M phase arrest and apoptosis in chronic myeloid leukemia","volume":"41","author":"Liu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34030_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4556","article-title":"Determination of GL-V9, a derivative of wogonin, in rat plasma by UPLC-MS\/MS and its application to a pharmacokinetic study after oral and pulmonary administration","volume":"33","author":"Xing","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2011.08.054","article-title":"GL-V9, a newly synthetic flavonoid derivative, induces mitochondrial-mediated apoptosis and G2\/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells","volume":"670","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e34030_bib38","article-title":"GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism","volume":"27","author":"Rui","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.heliyon.2024.e34030_bib39","first-page":"425","article-title":"GL-V9 ameliorates liver fibrosis by inhibiting TGF-\u03b2\/smad pathway","author":"Yabing","year":"2023","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34030_bib40","first-page":"28","article-title":"Characterization of cells with different mitochondrial membrane potential during apoptosis","volume":"68","author":"Lugli","year":"2018","journal-title":"Cytometry"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34030_bib41","article-title":"Pristimerin induces autophagy-mediated cell death in K562 cells through the ROS\/JNK signaling pathway","volume":"16","author":"Yu, Y.L.R.L.Z.B.L.Z","year":"2019","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.heliyon.2024.e34030_bib42","article-title":"Distinct interaction profiles of the second generation Bcr-Abl inhibitors nilotinib and bosutinib with the ABCG2 multidrug transporter","volume":"68","author":"Hegedus","year":"2008","journal-title":"Cancer Res."},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e34030_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125195","article-title":"Voice of cancer patients: patient experience regarding use of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"134","author":"Aggarwal","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34030_bib44","article-title":"GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism","volume":"27","author":"Wang","year":"2024","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34030_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41419-023-05903-z","article-title":"Inhibition of TRPV4 remodels single cell polarity and suppresses the metastasis of hepatocellular carcinoma","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34030_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.194.3.275","article-title":"P62dok, a negative regulator of ras and mitogen-activated protein kinase (Mapk) activity, opposes leukemogenesis by P210bcr-abl","volume":"194","author":"Cristofano","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e34030_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115442","article-title":"AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK\/miR-22\/HuR axis in chronic myeloid leukemia cells","volume":"209","author":"Lee","year":"2023","journal-title":"Biochem. Pharmacol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:51:46Z","timestamp":1773841906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024100618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024100618"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34030","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GL-V9 induce apoptosis of CML cells via MAPK signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34030"}}